Bulk Pharmaceutical API Sources for TALZENNA

Bulk Pharmaceutical API Sources for TALZENNA

Vendor	Vendor Homepage	Vendor Sku	API Url
DC Chemicals		DC8453
MedChemexpress MCE		HY-108413
AbaChemScene		CS-0028593

Bulk Active Pharmaceutical Ingredient (API) Sources for Talzenna (Alpelisib)

Last updated: July 29, 2025

---

Introduction

Talzenna (alpelisib) is an innovative oral kinase inhibitor formulated specifically for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2–) advanced breast cancer, particularly in cases with PIK3CA mutations. As a targeted therapy, the quality and supply of its active pharmaceutical ingredient (API) are critical to ensuring drug efficacy, safety, and regulatory compliance. This article examines key bulk API sources for Talzenna, analyzing the global landscape, quality standards, and supply chain considerations relevant to pharmaceutical manufacturers and stakeholders.

---

Overview of Alpelisib (Talzenna) API

Alpelisib is a small-molecule, selective phosphatidylinositol-3-kinase (PI3K) alpha isoform inhibitor. Its synthesis involves complex chemical processes requiring high purity, stereochemical accuracy, and rigorous impurity controls. The API's production scale depends on manufacturing capacity, quality assurance, and regulatory approvals.

The API's critical quality attributes (CQAs) include purity (>99%), controlled polymorphic form, and minimal residual solvents or process impurities, aligning with international standards such as USP, EP, and JP pharmacopoeias.

---

Global API Manufacturing Hubs

The primary regions supplying bulk alpelisib API include North America, Europe, and Asia, with notable contributions from the following countries:

1. United States and North America

   US-based and North American API manufacturers leverage advanced chemical synthesis capabilities, robust quality controls, and strong regulatory track records. Leading companies such as:

   • Boehringer Ingelheim: Known for high-quality APIs and integrated supply chains.
   • Amgen: Historically involved in kinase inhibitors and related APIs.

   Although not a primary producer of alpelisib, these firms often source from or collaborate with API manufacturers meeting stringent quality standards.

2. European Union

   European companies are renowned for adherence to stringent regulatory standards (EMA, ICH guidelines). Firms such as:

   • Novartis (Switzerland): Has extensive API manufacturing capabilities.
   • Siegfried (Switzerland): Known for custom synthesis and high-quality APIs.
   • Saint-Gobain Life Sciences: Specialized in fine chemicals and APIs.

3. Asian Market (China, India, South Korea)

   The Asian supply chain constitutes a significant portion of global API manufacturing due to cost efficiencies and increasing capacity:

   • WeiControl (China): Focuses on complex chemistries, including kinase inhibitors.
   • Hikal Ltd. (India): Offers API synthesis with ISO and cGMP compliance.
   • Jiande ChemPharm (China): Engages in contract manufacturing of APIs, including targeted cancer therapies.

---

Key API Manufacturers for Alpelisib

Given the proprietary and complex nature of alpelisib synthesis, only select manufacturers with validated processes and quality certifications are recognized as reliable API sources:

• Novartis: As the original developer and marketer of Talzenna, Novartis maintains in-house API production with multiple manufacturing sites compliant with good manufacturing practices (GMP). This vertical integration ensures supply security and quality consistency.

• External API Suppliers: Several CMOs (Contract Manufacturing Organizations) hold GMP certifications and supply alpelisib API to generic or biosimilar developers. These include:

  • Thermo Fisher Scientific: Provides custom synthesis services and bulk APIs.
  • Fujifilm Diosynth Biotechnologies: Known for complex molecule manufacturing.
  • Hanlim Pharm: South Korea-based, offering pharmaceutical synthesis capabilities.

---

Supply Chain and Regulatory Considerations

Secure and reliable API sourcing is paramount due to the complexity of alpelisib synthesis and regulatory implications:

• Quality Certifications: Suppliers must hold GMP compliance certificates from recognized authorities (FDA, EMA, PMDA, or equivalent).

• Supply Chain Transparency: Traceability in raw materials, process controls, and batch records.

• Regulatory Approvals: APIs intended for marketed drugs need to meet monograph standards, or else be characterized through strict validation.

• Risk Management: Diversification across suppliers and geographic regions minimizes supply disruptions, especially considering geopolitical and pandemic-related factors.

---

Emerging Trends in API Sourcing

• Increased Use of CMOs: Pharmaceutical companies increasingly outsource API production to specialized CMOs to mitigate costs and focus on formulation and marketing.
• Vertical Integration: Larger pharma firms like Novartis secure end-to-end control by maintaining internal API manufacturing.
• Regional Shifts: Growing capacity in India and China aims to meet global demand, though quality and regulatory compliance remain critical.

---

Concluding Remarks

For stakeholders involved in Talzenna manufacturing or distribution, sourcing high-quality alpelisib API hinges on understanding the geopolitical landscape, regulatory standards, and individual supplier capabilities. While Novartis primarily produces the API in-house due to proprietary synthesis routes, the global market for alpelisib API exists, primarily supplied by Asian manufacturers with strong cGMP credentials. Ensuring stringent quality assurance protocols and leveraging diversified supplier networks are vital for uninterrupted supply and compliance.

---

Key Takeaways

• Primary API Source: Novartis controls the manufacturing of alpelisib API for Talzenna, ensuring quality and supply continuity.
• Global Suppliers: Asian manufacturers, especially in China and India, provide scalable and cost-effective alternatives, subject to quality validation.
• Regulatory Compliance: Suppliers must demonstrate GMP adherence, quality certifications, and process transparency.
• Supply Chain Strategy: Diversify suppliers and geographic sources to mitigate risks associated with geopolitical, logistical, or regulatory disruptions.
• Emerging Markets: Asia’s API manufacturing capacity continues to grow, driven by technological advancements and government incentives.

---

FAQs

1. Who are the major API manufacturers for alpelisib (Talzenna)?
   Primary manufacturing is conducted by Novartis, with additional supply from GMP-certified contract manufacturers in Asia, including China and India.

2. What quality standards should API sources meet for Talzenna?
   Suppliers must adhere to cGMP standards and hold certifications from regulatory authorities like the FDA, EMA, or equivalent.

3. How does supply chain diversification impact Talzenna production?
   Diversification reduces dependency on a single source, mitigating risks of delays due to geopolitical issues or raw material shortages.

4. Are generic or biosimilar alpelisib APIs available?
   Currently, as Talzenna is a proprietary drug by Novartis, generic APIs are limited and often sourced through contract manufacturers with high quality standards.

5. What are the key considerations for evaluating API suppliers for Talzenna?
   Evaluate process capability, GMP certification, quality track record, raw material sourcing transparency, and regulatory compliance.

---

References

1. [1] US Food and Drug Administration. (2022). Guidance for Industry: Content and Format of Chemistry, Manufacturing, and Controls (CMC) Information for Human Prescription Drug and Biological Product Applications.
2. [2] European Medicines Agency. (2021). Good Manufacturing Practice (GMP) guidelines.
3. [3] Novartis Annual Report 2022. Manufacturing capabilities and supply chain overview.
4. [4] Healthcare industry reports on global API manufacturing capacity.
5. [5] Contract Manufacturing Organizations (CMOs): Market Reports and Profiles.

Note: These references are indicative; actual citations should include detailed publication data.